9 Things to Know About Low-Dose Naltrexone and Its Emerging Role in Menopause Inflammation and Pain
When the pain feels like it came out of nowhere and nothing obvious explains it, it's easy to feel dismissed — by doctors, by test results, by the people around you. LDN is one of those topics that comes up constantly in perimenopause communities, often with a lot of hope attached. That hope isn't unreasonable, but it deserves to be held alongside honest information about how early the research still is.
Learn more about Rose →LDN Is Standard Naltrexone at a Much Smaller Dose — and That Difference Matters
Naltrexone is an FDA-approved opioid antagonist typically prescribed at 50mg daily for alcohol and opioid use disorders. Low-dose naltrexone (LDN) refers to doses generally between 1.5mg and 4.5mg — roughly one-tenth of the standard amount — which appear to act through an entirely different biological mechanism. At this micro-range, the drug briefly and transiently blocks opioid receptors rather than sustaining blockade, and this transient effect is thought to trigger a rebound increase in the body's own endorphin production.
Its Primary Proposed Mechanism Is Microglial Modulation, Not Opioid Blockade
The most researched mechanism behind LDN's anti-inflammatory effects involves microglia — the brain's resident immune cells. When microglia become chronically activated, as they appear to do in conditions involving neuroinflammation, they release pro-inflammatory cytokines that contribute to pain amplification, fatigue, and cognitive symptoms. LDN is thought to antagonise toll-like receptor 4 (TLR4) on microglia, dampening this activation and reducing the downstream inflammatory signalling without broadly suppressing the immune system.
Estrogen Decline Creates a Neuroinflammatory Environment That LDN May Help Address
Estrogen has well-documented neuroprotective and anti-inflammatory properties, and its decline during perimenopause is associated with increased microglial reactivity and elevated circulating inflammatory markers including IL-6 and TNF-alpha. This shift helps explain why many women develop new-onset pain, hypersensitivity, and cognitive difficulties that don't respond to conventional pain management. The hypothesis — still being tested — is that LDN's microglial-calming effects could offer a meaningful adjunct for women whose symptoms are driven substantially by this neuroinflammatory shift.
Fibromyalgia Research Provides the Strongest Human Evidence So Far
A small but well-designed crossover trial published in PAIN (Younger et al., 2013) found that LDN at 4.5mg significantly reduced fibromyalgia pain scores compared to placebo, with participants also reporting improved mood and general wellbeing. The effect size was modest but meaningful, and the side effect profile was notably mild. Because fibromyalgia shares considerable overlap with the centralised pain and fatigue patterns many menopausal women describe, this research is frequently cited as a rationale for off-label use — though direct menopause-specific trials have not yet been conducted.
LDN Has Also Shown Promise in Multiple Sclerosis and Crohn's Disease
Small randomised trials and observational studies in multiple sclerosis and Crohn's disease have reported improvements in fatigue, quality of life, and inflammatory markers with LDN use. These conditions, like menopause-related neuroinflammation, involve dysregulated immune signalling and microglial involvement, which strengthens the biological plausibility of LDN's effects across conditions rather than in one isolated context. However, sample sizes across these trials remain small, and larger confirmatory studies are still needed before LDN can be considered evidence-based treatment in any of these areas.
The Evidence for LDN in Menopause Specifically Is Currently Anecdotal and Observational
No randomised controlled trials have yet directly examined LDN in perimenopausal or menopausal women as a primary study population. Much of what circulates in online communities and some integrative medicine practices is based on extrapolation from other chronic pain and inflammatory conditions, patient-reported outcomes, and case series rather than controlled data. This does not mean the effect is not real — it means the evidence hierarchy is not yet strong enough to make firm recommendations, and honest framing of that gap is important.
Side Effects Are Generally Mild but Sleep Disruption Is Worth Knowing About
LDN is widely reported to be well tolerated, with the most common side effect being vivid dreams or sleep disruption, particularly when the dose is taken at night. This occurs because LDN transiently blocks opioid receptors during sleep, when endogenous opioid activity is naturally higher. Many prescribers shift the dosing to morning hours to reduce this effect, and it often resolves within the first two to four weeks as the body adjusts — though for women already dealing with disrupted sleep in menopause, it is a relevant consideration to discuss with a prescriber.
LDN Requires a Prescription and Is Usually Compounded — Not Available Off the Shelf
Because naltrexone is only commercially available in 50mg tablets, the low doses used therapeutically must be prepared by a compounding pharmacy, which means LDN is not a supplement someone can purchase over the counter. It requires a prescription from a physician familiar with off-label use, which in practice means access varies considerably depending on geography and healthcare system. Women interested in exploring LDN should raise it with a menopause specialist or an integrative medicine physician who can assess individual suitability, current medications, and monitoring needs.
LDN Is Not a Replacement for Hormone Therapy and Shouldn't Be Framed That Way
Hormone therapy — where appropriate and suitable for an individual — addresses the root hormonal cause of many menopausal symptoms including the neuroinflammatory cascade that LDN is theorised to help modulate downstream. LDN, by contrast, works on a symptomatic and mechanistic pathway that does not restore estrogen's broader tissue-protective, cardiovascular, and bone-protective effects. For women who cannot or choose not to use hormone therapy, LDN may eventually prove to be a useful tool for pain and inflammation management specifically — but the two approaches address fundamentally different aspects of menopause biology and are not interchangeable.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.